Transcranial magnetic stimulation devices for depression, OCD, anxiety, and smoking cessation. A fast-growing category with only 6-8 major players. Psychiatrists making $60K-$250K purchase decisions with almost zero independent comparison content available.
Transcranial magnetic stimulation uses electromagnetic pulses to depolarize cortical neurons noninvasively. Standard TMS (NeuroStar) uses a figure-8 coil to stimulate the left dorsolateral prefrontal cortex at approximately 2cm depth, targeting depression circuits. Deep TMS (BrainsWay) uses an H-coil that reaches 6cm depth, allowing broader cortical activation. Treatment protocols range from 19-37 minutes per session, typically delivered 5 days per week for 4-9 weeks depending on the platform.
TMS is the fastest-growing physician-owned device category outside of aesthetics. The market is consolidated among 6-8 major players. NeuroStar (Neuronetics, NASDAQ: STIM) has the largest installed base in the US with over 5 million treatments delivered. BrainsWay (NASDAQ: BWAY) holds the deep TMS niche with FDA clearances for OCD and smoking cessation that competitors lack. BTL's EXOMIND entered the US market in 2024 with a 6-session protocol that dramatically undercuts the standard 36-session model.
EXOMIND's 6-session protocol is the biggest disruption in the category since FDA cleared TMS in 2008. If the clinical outcomes hold up at scale, the entire economic model of TMS practices changes. Standard TMS practices generate revenue from 36 reimbursed sessions per patient. EXOMIND practices would need 6x the patient volume to match revenue. Insurance reimbursement codes and protocols haven't caught up. Meanwhile, NeuroStar lost a major insurance contract negotiation in late 2025, and STIM stock has been volatile.
Psychiatrists are the primary buyers, often opening dedicated TMS service lines within an existing practice. Group psychiatry practices are the highest-volume buyers because they can refer internally. Multi-specialty practices add TMS as a cash-pay or insurance hybrid offering. Neurology practices buy TMS less often, primarily for migraine indications.
A starting point: NeuroStar
NeuroStar (Neuronetics) is the first published profile in this category to review, not a claim that it is best for every practice. Psychiatrists starting a TMS practice who want the most established platform with the strongest insurance reimbursement track record. Practices that value the largest clinical dataset.
Review its documented capabilities and limits, then compare them with your indication, patient mix, service requirements, and written quote. Strongest in category. 100+ published studies. 5M+ treatment outcomes registry. Multiple FDA clearances backed by large RCTs.
One tradeoff to test: Standard TMS depth (~2cm) vs BrainsWay's deep TMS (~6cm). Device Pulse does not treat manufacturer coverage, listing order, or a clearance record as proof of comparative superiority.
Transcranial Magnetic Stimulation (focused figure-8 coil)
NEW$80,000-$150,000
USED$40,000-$80,000
Psychiatrists starting a TMS practice who want the most established platform with the strongest insurance reimbursement track record. Practices that value the largest clinical dataset.
Deep TMS (H-Coil Technology) for deeper brain stimulation
NEW$100,000-$200,000
USED$50,000-$120,000
Psychiatrists who want the deepest stimulation available and value the expanded indication set (OCD, smoking cessation). Practices serving treatment-resistant patients where standard TMS depth may be
High-volume TMS practices that want to increase daily patient throughput through TBS. Psychiatrists opening new TMS practices who want faster sessions as a competitive differentiator.
Navigated Brain Stimulation (NBS) with MRI-Guided Targeting
NEW$150,000-$250,000
USED$70,000-$140,000
Academic medical centers, research programs, and specialty psychiatry practices that value MRI-guided targeting and can absorb the higher capital and per-patient costs.
Device selection in this category breaks into six decision factors that matter more than the specs on a sales sheet. Practices that get the selection right match the device to their specific economics rather than buying the platform with the best marketing.
Practice type considerations. Dermatologists, plastic surgeons, med spas, and multi-specialty practices have different priorities. Specialty practices weight clinical evidence heavily. Cash-pay med spas weight throughput and patient demand. Multi-specialty groups weight integration with existing platforms. Start here before looking at any individual device.
Patient demographics. Skin type range, age distribution, average household income, and willingness to pay per-session pricing all affect which device fits. Markets with price-sensitive patients need different devices than concierge practices. Run a realistic patient persona before evaluating specific platforms.
Budget scope. Set a practice-specific capital ceiling, then compare the full five-year obligation: financing, software, accessories, consumables, service, staffing, downtime, and exit terms. Do not infer demand from the size of the purchase.
New vs used and refurbished. Compare exact configurations and written terms. Verify title, software eligibility, service history, transfer fees, warranty, parts, training, and inspection results before treating a lower used asking price as savings.
Consumables and operating costs. Request a current itemized schedule for consumables, software, preventive maintenance, repairs, and required accessories. Model those costs at the practice's measured volume.
Clinical evidence requirements and device ecosystem fit. Academic and research-oriented practices weight evidence quality heavily. High-volume cash-pay practices weight brand recognition. Existing device ecosystems create cross-sell and training efficiencies that often tilt the decision toward one manufacturer over another.
Insurance reimbursement track record (NeuroStar leads here)
Treatment depth needed (standard 2cm vs deep 6cm coil)
Patient population (treatment-resistant vs first-line)
Practice referral capacity (TMS needs steady patient flow)
Operator training and certification requirements
Market Trends
New TMS systems still command $60K-$250K. Used NeuroStar units have held value better than aesthetic devices, trading at $40K-$80K. The big question is whether EXOMIND's 6-session protocol gains insurance reimbursement parity. If yes, the category economics flip. If no, EXOMIND becomes a cash-pay alternative for patients who can't commit to 9 weeks of daily treatment. NeuroStar's installed base advantage is durable but not unlimited. BrainsWay keeps winning in OCD and smoking cessation through its expanded clearances.
Current FDA records can show clearance scope, recalls, and other regulatory activity, but they do not establish comparative quality or future support. Before a multi-year agreement, verify the exact legal counterparty, written service obligations, parts access, software support, transfer terms, and available public filings where relevant.
Frequently Asked Questions
Which tms devices devices does Device Pulse currently cover?
Current published profiles include NeuroStar, BrainsWay Deep TMS, EXOMIND, MagVenture TMS Therapy. This is a coverage list, not a complete market inventory or a ranking. The right short list depends on indication, patient mix, service support, evidence requirements, and verified commercial terms.
How much do tms devices devices cost?
The category record carries a legacy editorial range of $60,000-$250,000. It is not a dated sample of completed transactions. Compare current itemized quotes for the same model, configuration, software, accessories, service, training, and delivery scope.
Which specialties buy tms devices devices?
Primary buyers include Psychiatry, Neurology. The buyer profile varies by device tier. Premium platforms go to high-volume practices with established patient flow. Mid-range platforms fit specialty practices building a new service line. Starter-tier platforms work for practices testing category demand before committing to a flagship purchase.
How fast is the tms devices market growing?
The global tms devices market is approximately $1.4B (2025) with 10% CAGR projected growth. Growth is not uniform across manufacturers. Category leaders typically hold or grow share while mid-tier brands compete on price and newer entrants try to win on clinical evidence or technology differentiation. Physicians making purchase decisions should weigh manufacturer momentum alongside headline market growth.
What's changing in the tms devices category right now?
EXOMIND's 6-session protocol is the biggest disruption in the category since FDA cleared TMS in 2008. If the clinical outcomes hold up at scale, the entire economic model of TMS practices changes. Standard TMS practices generate revenue from 36 reimbursed sessions per patient. EXOMIND practices would need 6x the patient volume to match revenue. Insurance reimbursement codes and protocols haven't caught up. Meanwhile, NeuroStar lost a major insurance contract negotiation in late 2025, and STIM stock has been volatile.
How do I choose the right tms devices device?
The decision framework for this category covers practice type, patient demographics, budget, existing device ecosystem, clinical evidence requirements, and consumable economics. Match the device to your specific practice rather than buying what a sales rep recommends as a general best choice. Our specialty guides break this down by practice type.
Are used or refurbished tms devices devices worth buying?
A used device can reduce capital cost, but the discount and risk are unit-specific. Verify serial-number history, title, software, handpieces, service records, transfer fees, warranty, parts access, and the exact cleared model before comparing a used offer with a new quote.
What are the biggest risks in buying a tms devices device?
The top risks: buying ahead of patient demand, choosing a device based on sales rep claims without independent diligence, ignoring consumable cost structures, and failing to verify manufacturer service support in your region. Physicians who project optimistic treatment volumes and finance a large purchase based on those projections often regret the decision within 18 months. Run your numbers on conservative assumptions before signing a contract.